EditForce
Fukuoka, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A biotech company developing programmable RNA-editing therapies using a proprietary PPR protein platform, initially targeting rare genetic diseases.
Rare DiseaseNeurological
Technology Platform
A proprietary platform using engineered PPR (pentatricopeptide repeat) proteins that bind specific RNA sequences and are fused to effector domains (e.g., DYW deaminase) to perform precise RNA editing and modulation.
Opportunities
The platform's programmability and compact size allow targeting of a wide range of RNA-related diseases, with significant potential in rare genetic disorders and expansion into non-therapeutic areas like agriculture.
Risk Factors
As a preclinical, private company, it faces significant development and regulatory risks, competition from established RNA-targeting modalities, and the need to secure substantial funding to advance programs to the clinic.
Competitive Landscape
Competes with ASO, siRNA, and ADAR-based RNA editing platforms; key differentiation is its protein-only, single-component editor designed for high specificity and AAV deliverability.